RankAlpha logo
Back to Rankings

PTCT

PTC TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Q2 Sephience revenue of $151 million and raised 2026 product-revenue guidance provide an operating base; sustained uptake, ST-920 submission and votoplam progress could support upside. These are conditional outcomes, not Q3 results.
Posture
Mixed
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-10-29 · AMC.
What can break
ST-920 rolling BLA completion, FDA review and eventual commercialization remain uncertain despite the completed acquisition. [#8-K-2026-09-21]
Momentum
35
Value
53
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $65.00 · Bull $82.00 · Bear $45.00Analysis 2026-10-23; returns require an exact persisted reference.
Earnings
2026-10-29 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-23 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $97.81
Why
Momentum35 · Δ7d +9.0
Value53 · Δ7d -0.2
Sentiment62 · Δ7d -12.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29 · AMC.
  • • Sentiment remains the lead driver in the composite, 7D delta -12.9.

Contradictions & invalidation

  • • ST-920 rolling BLA completion, FDA review and eventual commercialization remain uncertain despite the completed acquisition. [#8-K-2026-09-21]
  • • Sephience uptake and reimbursement must sustain the raised 2026 product-revenue guidance; Q3 figures are not yet available. [#SEC-8K-2026-07-30]
  • • Q3 commercial uptake or guidance could disappoint, while ST-920 submission and later review, votoplam development, reimbursement and portfolio spending carry execution risk.

Catalyst clock

2026-10-29 · AMC

Q3 results and business update on October 29—not October 22

Lead driver: Sentiment · See AI snapshot
Momentum
35
8% active weight
Current posture
7d trendImproving
Δ7d
+9.0
Δ21d
+20.7
Value
53
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.6
Sentiment
62
45% active weight
Current posture
7d trendSoftening
Δ7d
-12.9
Δ21d
-16.3
Why this grade

Composite grade C. Momentum 34.6 / Value 52.8 / Sentiment 61.8

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-23. Scenario method

B+
Bull case
25%
Probability
Target price
$82.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$65.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$5.06B
Beta
0.48
Shares Out
83.46M
P/E (TTM)
9.0
P/S (TTM)
3.46
P/FCF (TTM)
8.74
Rev YoY
+101.5%
EPS YoY
-210.6%
Gross Margin
+89.0%
Op Margin
+11.6%
Net Debt
-$1.55B
Current Ratio
3.39
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data